Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.6 DKK | +1.60% | -1.10% | +50.79% |
May. 30 | Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review | CI |
May. 03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 |
End-of-day quotes
Sector Other Pharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
4.91B | ||||||
739B | ||||||
598B | ||||||
353B | ||||||
318B | ||||||
285B |
- Stock Market
- Equities
- ALK B Stock
- Charts ALK-Abelló A/S
- Sector Chart